Specialist in Pneumology, member FMH
Vice president of Vaud Lung League
Medical Officer of Public Health for tuberculosis VD (Tuberculosis 10%)
Medical Advisor in Respiratory Medicine at the Vaud Lung League (10%)
Senior consultant at the Division of Respiratory Medicine (30%) University Hospital of Lausanne Switzerland (CHUV) and private practice in Pulmonary Medicine at Nyon (60% of activity)
Chief of Residents, Respiratory Division CHUV
Chief of Residents (Chef de Clinique) Thoracic Surgery Division CHUV
Respiratory Medicine as MD at University Hospital of Geneva
Respiratory Medicine training as a resident (MD) at Rolle Hospital
Respiratory Medicine Residency (resident) at CHUV
Chief of Residents and residency of Internal Medicine Central Military Hospital
After completing her medical studies in 1995 at the University of Buenos Aires in Argentina (UBA), Jesica Mazza-Stalder specialised in internal medicine and began her training in pulmonology at the Fundacion Favaloro in Buenos Aires. When she arrived in Switzerland in 2001, she continued her training at the CHUV, first as a pneumology intern, then at Rolle Hospital, and finally at the HUG.
In 2007, on her return to the CHUV, she became head of clinic in the Department of Thoracic Surgery, then in the Department of Pneumology until April 2011, when she was appointed a registered doctor.
Jesica Mazza-Stalder's research focuses on cystic fibrosis, lung transplantation and tuberculosis. As part of her work in the Pneumology Department, and in particular at the tuberculosis clinic (DAT), links have been established between the Vaud Lung League and public health.
Member of the Board Swiss TB
Vice President of Lung League Vaud
International Union against Tuberculosis and Lung disease
Swiss Respiratory Society
European Respiratory Society
Federal Swiss Diploma
Doctorate Unil University of Lausanne Switzerland
FMH Respiratory Medicine
Internal Medicine Specialist (Buenos Aires- Argentina)
Medical Doctor education Faculty of Medicine Buenos Aires University (UBA)
Tadolini, GB Miggliori et al Eur Respir J may 2020
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
Borisov S, et al....Mazza-Stalder J, Nicod LP, Miggliori GB Eur Respir J 2019 Dec 19,54 (6) Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
J Mazza-Stalder, E Chevallier, O Opota, A Carreira, K Jaton, E Masserey, J P Zellweger, L P Nicod. Frontiers in Medicine. Published June 2019. Improvement in tuberculosis outcomes with a combined medical and social approach
Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clinic Microbiol Infection 2019 Nov doi: 10.1016/j.cmi.2019.03.021. Epub 2019 Mar 28
Zakham F1, Laurent S1, Esteves Carreira AL2, Corbaz A2, Bertelli C1, Masserey E3, Nicod L2, Greub G1, Jaton K1, Mazza-Stalder J2, Opota O1. New Microbes New Infect. 2019 Jun 29; 31:100582. doi: 0.1016/j.nmni.2019.100582. eCollection 2019 Sep. Whole-genome sequencing for rapid, reliable and routine investigation of Mycobacterium tuberculosis transmission in local communities
Simon A, Opota O, Mazza-Stalder J, Nicod L, Greub G, Nicod L, Jaton K. Added diagnostic value of 16S rRNA gene pan mycobacterial for nontuberculous mycobacterial infections: a 10 year retrospective study
O Opota, F Zakham, J Mazza-Stalder, L Nicod, G Greub, K Jaton. Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low Prevalence Setting. J Clin Microbiol 2018 57:e01717-18
Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, and the MDR-TB Cluster Consortium. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018;18(4):431-40
Opota O, Senn L, Prod'hom G, Mazza Stalder J, Tissot F, Greub G, Jaton K. Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clin Microbiol Infect. 2016 Jul;22(7):613-9. doi: 10.1016/j.cmi.2016.04.010. Epub 2016 Apr 29
Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L. Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country.J Clin Microbiol. 2016 Jul;54(7):1862-70. doi: 10.1128/JCM.00126-16.
Rozot V, Amelio P, Vigano S, Mazza-Stalder J, Idrizi E, Day Cheryl, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D, Bart P. A, Hanekom W, Scriba Th, Nicod L, Pantaleo G and Harari A. Clinical infectious disease 2015. Combined Use of M Tuberculosis-specific CD4 and CD8 T cell is a Powerful Diagnostic tool of Active Tuberculosis
Bridevaux P-O, Aubert J-D, Soccal P M, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle, Nicod L. P et al Thorax september 2013 Incidence and Outcomes of respiratory viral infections in lung transplant recipients: a prospective study
Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, Maillard M, Dorta G, Mazza-Stalder J, Bart PA, Roger T, Calandra T, Nicod L, Harari A. Eur J Immunol. 2013 Apr; 43(4):939-48. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+T cells in active disease
Rozot V, Mazza-Stalder J, Nicod L. P, Harari A. et al EJI 2013. Mycobacterium tuberculosis-specific CD8+ T Cells are functionally and phenotypically different between latent infection and active disease
Mazza-Stalder J, Nicod L., Janssens JP. Revue des Maladies respiratoires April 2012. Extra-pulmonary tuberculosis
Harari A, R Rozot V, Bellutti Enders F, Perreau M, Mazza-Stalder J, Nicod L., Cavassini M, Calandra Th, Lazor Blanchet K, Jaton K, Faouzi M, Day Ch, Willem A. Hanekom, Bart P-A and Pantaleo G. Nature Med 2011. Dominant TNF-a Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses Discriminate Between Latent Infection and Active Disease
Uçkay I, Gasche-Soccal PM, Kaiser L, Stern R, Mazza-Stalder J, Aubert JD, van Delden C. J Heart Lung Transplant. 2010 Mar; 29(3):299-305. Epub 2009 Oct 17. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy
Boillat Blanco N, Kuonen R, Bellini C, Manuel O, Estrade C, Mazza-Stalder J, Aubert JD, Sahli R, Meylan P. Transpl Infect Dis. 2010 Aug 30. Chronic norovirus gastroenteritis in a double hematopoietic stem cell and lung transplant recipient
Mazza-Stalder J, Lador F, Soccal-Gasche P, Aubert J. Evaluation of pulmonary arterial pressure in lung transplant candidates: transthoracic echocardiographie versus right heart catheterization. "Best poster at the Swiss Society of Pulmonary Hypertension. ERS Vienna 2009/ and 4th International Congress of the Swiss Society for Pulmonary Hypertension. SSPH Zurich 2009: Best Poster
Mazza-Stalder J, Janton-Ogay K, Nicod L. Revue medicale Suisse nov 2009. Non tuberculous mycobacteria pulmonary disease: what's new?
Mazza-Stalder J, Sistek, J. P. Revelly, S. D. Qanadli, A. Sauty. Massive haemoptysis in cystic fibrosis adult patients. ERS 2008. P1244. 5.10.2008
Mazza-Stalder J, Siegrist CA, Janssens JP. Rev Med Suisse. 2005 Nov 16; 1(41):2645-6, 2649-51. Immunization and immuno-modulation for prevention of respiratory tract infections
Mazza-Stalder J, Sauty A. 48h-continuous interstitial glucose monitoring in non-diabetic cystic fibrosis patients: a pilot study. Journal of Cystic Fibrosis 2 (suppl1), pp. S79, 2003
Mazza-Stalder J, Sauty A. Le syndrome hépatopulmonaire (SHP). Médecine et Hygiène 2458, 12 Nov 2003
Mazza-Stalder J, Sauty A. Significance of macrophage predominance in pleural effusions. Oral presentation ERS congress Schweiz Med Forum suppl 7, pp 20S 2002
